6-position Substituent Contains Hetero Ring Patents (Class 514/196)
  • Patent number: 10227331
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, David Hunter, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu, Yunfeng Bai, Zhixiang Zheng, Xu Zhang
  • Patent number: 10221163
    Abstract: The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Bennett, Jinlong Jiang, Alexander Pasternak, Shuzhi Dong, Xin Gu, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Yuhua Huang, Dexi Yang, Katherine Young, Li Xiao, Zhibo Zhang, Jianmin Fu
  • Patent number: 10028963
    Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: July 24, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gurudatt A. Chandorkar, Jennifer A. Huntington, Tara Parsons, Obiamiwe C. Umeh
  • Patent number: 9872906
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: January 23, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Patent number: 9309232
    Abstract: Antibacterial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit or parasite or bacterial growth.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: April 12, 2016
    Assignees: Board of Trustees of Northern Illinois University, Beryllium Discovery Corp.
    Inventors: Timothy J. Hagen, Zheng Zhang, Zachary Lazowski, Michael Clare, Darren W. Begley
  • Publication number: 20150099714
    Abstract: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 9, 2015
    Inventors: Julie F. Liu, Xuejun Tang, Scott L. Harbeson, Craig E. Masse
  • Publication number: 20150072957
    Abstract: This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Applicant: Calixa Therapeutics, Inc.
    Inventors: Jan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
  • Patent number: 8968781
    Abstract: The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: March 3, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Walter G. Gowan, Jr., Dennis D. Keith, Sandra O'Connor
  • Publication number: 20150045337
    Abstract: The present invention relates to a composition, the composition including a therapeutically effective amount of at least one active agent, and a base including, an amount of colloidal silica; at least one oil; and at least one surfactant, wherein the viscosity of the composition is below 1000 mPas at a shear rate of 100 l/s and at a temperature of 20° C.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 12, 2015
    Inventors: Fadil Al Alawi, Olaf Bork, Ian George Tucker
  • Publication number: 20150018312
    Abstract: Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.
    Type: Application
    Filed: May 4, 2014
    Publication date: January 15, 2015
    Applicant: WOCKHARDT LTD.
    Inventors: Vijaykumar Jagdishwar PATIL, Ravikumar TADIPARTHI, Satish BIRAJDAR, Sachin BHAGWAT
  • Publication number: 20150011488
    Abstract: Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical resection or removal of the genital wart in such form of a cream, ointment, paste or solution, (D) following chemical resection or extirpation of the genital wart in such form, (E) following surgical resection or removal of the genital wart in such form, wherein said Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins both provide antiviral activity against multiple strains of human pappilomavirus (HPV) and promote healing following resection polymers contained in a vehicle. Disclosed are the compositions, therapeutical kits containing such composition, methods of treatment using such composition, and methods of enhancing the stability of such composition.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 8, 2015
    Applicant: CACAO BIO-TECHNOLOGIES, LLC
    Inventors: Daniel PRESTON, Randall B. MURPHY
  • Publication number: 20140364384
    Abstract: The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable.
    Type: Application
    Filed: April 23, 2014
    Publication date: December 11, 2014
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Richard J. Melker, Donn Michael Dennis, Christopher D. Batich, Mark S. Gold
  • Patent number: 8889733
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: November 18, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
  • Publication number: 20140200189
    Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.
    Type: Application
    Filed: January 14, 2013
    Publication date: July 17, 2014
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
  • Publication number: 20140128335
    Abstract: The present invention relates to the use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment of bacteria including those presenting multiple drug resistance (MDR), in particular as efflux pump inhibitors. It also relates to novel polyaminoisoprenyl derivatives, compositions comprising the same, process for preparing the same, and use thereof in antibiotic or antiseptic treatment.
    Type: Application
    Filed: February 23, 2012
    Publication date: May 8, 2014
    Applicants: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE CORSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Michel Bolla, Jean Michel Brunel, Joseph Pierre Felix Casanova, Vannina Lorenzi, Liliane Berti
  • Publication number: 20140107092
    Abstract: Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Inventors: Matthew Meyerson, Aleksandar Kostic
  • Publication number: 20140088069
    Abstract: An antibacterial composition is provided including a combination of a ?-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided.
    Type: Application
    Filed: November 29, 2013
    Publication date: March 27, 2014
    Inventors: Eric D. Brown, Maya Farha, Alexander Leung, Gerry Wright, Kalinka Koteva, Ted Sewell, Linda Ejim
  • Publication number: 20140073591
    Abstract: Multidrug resistance reversers of the d-tetrandrine family are used in conjunction with penicillins and other principle drugs used to treat MRSA.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 13, 2014
    Applicant: CBA Pharma, Inc.
    Inventors: Wayne Michael Putnam, Beth D. Gudeman
  • Publication number: 20140066365
    Abstract: A product comprising at least one given antibiotic and a calixarene for use as medicament.
    Type: Application
    Filed: April 11, 2012
    Publication date: March 6, 2014
    Inventors: Marion Grare, Raphaël, Emmanuel Duval
  • Publication number: 20140038883
    Abstract: The present invention relates to compounds of formula (I), where R1 and R2, identical or different, are each independently a hydrogen atom or a non-substituted or substituted (C1-C12) alkyl group; R3 is a hydrogen atom or a non-substituted or substituted (C1-C6) alkyl group; R4 is a non-substituted or substituted (C1-C12) alkyl group or an aryl or heteroaryl group, said aryl and heteroaryl groups being non-substituted or substituted; and R5 is a non-substituted or substituted (C1-C12) alkyl group; or R4 and R5 are bonded to one another by a saturated hydrocarbon chain having 3 or 4 carbon atoms, optionally in hydrated form or in the form of a salt that is acceptable for being administered to animals or plants, for the use thereof as a potentiator of the effect of an antimicrobial agent or for the use thereof as an antimicrobial agent.
    Type: Application
    Filed: January 27, 2012
    Publication date: February 6, 2014
    Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JOSEPH FOURIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, HOSPICES CIVIL DE LYON
    Inventors: Anne Doleans-Jordheim, Jean Freney, Charles Dumontet, Ahcene Boumend Jel, Jean-Baptiste Veron, Yung-Sing Wong
  • Publication number: 20130338130
    Abstract: Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.
    Type: Application
    Filed: August 19, 2013
    Publication date: December 19, 2013
    Applicant: Biogenic Innovations, LLC
    Inventors: Rodney Benjamin, Anthony L. Keller, Jeffrey Varelman
  • Publication number: 20130296228
    Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.
    Type: Application
    Filed: April 22, 2013
    Publication date: November 7, 2013
    Inventors: Mahesh Vithalbhai PATEL, Sachin Subhash Bhagwat, Mohammad Alam Jafri
  • Publication number: 20130281359
    Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; and R1 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 24, 2013
    Inventors: Samarendra N. MAITI, Dai Nguyen, Jehangir Khan, Rong Ling
  • Publication number: 20130274235
    Abstract: Provided herein are methods and compositions for the treatment of motor neuron diseases including, for example, amyotrophic lateral sclerosis. Suitable therapeutic agents include, for example, agents that up-regulate the expression IGF-II or guanine deaminase in a cell.
    Type: Application
    Filed: October 10, 2011
    Publication date: October 17, 2013
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ole Isacson, Anna Charlotta Teresia Magnuson Osborn
  • Publication number: 20130209522
    Abstract: In some embodiments, the invention provides an implant comprising a uniform mixture of degradable polymer, bone, and a drug. In some embodiments, the drug comprises an antibiotic. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for an amount of time longer than an amount of time that a pathogen is senescent. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for at least eight weeks, or at least ten weeks, or at least twelve weeks post-implantation. In some embodiments, the therapeutic level is maintained at an implantation site of the implant. In some embodiments, the implant is a solid, a paste, or a liquid. In some embodiments, the solid implant is carved or molded for insertion into a site of implantation in a vertebrate host prior to implantation. In some embodiments, the paste implant hardens following implantation. In some embodiments, the liquid implant is used to coat a prosthesis (e.g.
    Type: Application
    Filed: February 5, 2013
    Publication date: August 15, 2013
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: UNIVERSITY OF UTAH RESEARCH FOUNDATION
  • Publication number: 20130189368
    Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.
    Type: Application
    Filed: June 1, 2011
    Publication date: July 25, 2013
    Applicant: UNIVERSIDADE FEDERAL DE OURO PRETO
    Inventors: Vanessa Carla Furtado Mosqueira, Raquel Silva Araújo, Humberto de Mello Brandão
  • Patent number: 8461143
    Abstract: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: June 11, 2013
    Assignee: Taro Pharmaceuticals North America, Inc.
    Inventors: Shen Gao, Daniel A. Moros, Satish Asotra
  • Publication number: 20130143856
    Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.
    Type: Application
    Filed: January 21, 2011
    Publication date: June 6, 2013
    Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FORCORPORATE COLLABORATION
    Inventors: Kyeong Kyu Kim, Sung Wook Kang
  • Patent number: 8435565
    Abstract: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition. The composition may be administered to a body site in need of the same by providing a first aliquot portion of a reaction mixture which includes the reactants and a bioactive agent. A kit which includes a double syringe respectively containing the first and second aliquot portions of the reaction mixture may be provided so that the same may be mixed just prior to use.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: May 7, 2013
    Assignee: Royer Biomedical, Inc.
    Inventor: Garfield P. Royer
  • Publication number: 20130065874
    Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
    Type: Application
    Filed: September 7, 2012
    Publication date: March 14, 2013
    Applicant: Cubist Pharmaceuticals, Inc.
    Inventors: Gurudatt A. Chandorkar, Jennifer A. Huntington, Tara Parsons, Obiamiwe C. Umeh
  • Publication number: 20130064772
    Abstract: Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO2 at the wound site which forms carbonic acid, lowers the pH at the pH sensitive components, and thus results in rupture of the liposome.
    Type: Application
    Filed: September 7, 2012
    Publication date: March 14, 2013
    Inventors: Gerald F. Swiss, Stefan Schwabe, Robert M. Moriarty
  • Publication number: 20130053336
    Abstract: The invention relates to a method for treating infections of bacteria of the Chlamydiaceae family using a ?-lactam. The invention also relates to a method for treating diseases caused by an infection of bacteria of the Chlamydiaceae family using a ?-lactam.
    Type: Application
    Filed: January 13, 2011
    Publication date: February 28, 2013
    Inventors: Philippe Verbeke, Maud Dumoux, Colette Kanellopoulos
  • Publication number: 20130018029
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: July 16, 2012
    Publication date: January 17, 2013
    Inventor: Chongxi YU
  • Publication number: 20120301422
    Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.
    Type: Application
    Filed: January 16, 2003
    Publication date: November 29, 2012
    Inventor: Petrus Johannes Meyer
  • Publication number: 20120245128
    Abstract: The present disclosure in general relates to methods, systems, and apparatus for identifying modification of a medicinal compound exposed to a sample for use in determining which treatment to provide to a subject in need thereof.
    Type: Application
    Filed: March 26, 2012
    Publication date: September 27, 2012
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Anthony M. Haag, Norbert K. Herzog, David W. Niesel
  • Publication number: 20120225128
    Abstract: The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Inventors: Andreas JORDAN, Norbert Waldoefner, Regina Scholz
  • Publication number: 20120172292
    Abstract: This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO scavenger.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Applicant: NEW YORK UNIVERSITY
    Inventors: Evgeny A. Nudler, Ivan Gusarov
  • Publication number: 20120157371
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: December 12, 2011
    Publication date: June 21, 2012
    Inventors: Chongxi YU, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
  • Publication number: 20120149672
    Abstract: Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.
    Type: Application
    Filed: February 17, 2012
    Publication date: June 14, 2012
    Inventors: Rodney Benjamin, Jeffrey Varelman, Anthony Keller
  • Publication number: 20120122831
    Abstract: Described herein is a method and a device for expediting delivery of an agent to a damaged bacterial cell. In one embodiment, the methods and devices are useful for screening candidate antibiotics. In another embodiment, the methods and devices described herein are used to determine susceptibility of bacteria to an antibiotic. The methods also provide a method for determining an appropriate antibiotic to treat an individual having a bacterial infection.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 17, 2012
    Applicants: FRAUNHOFER USA, INC., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Alexis Sauer-Budge, Andre Sharon, Maxim Kalashnikov, Holger Wirz
  • Publication number: 20120115820
    Abstract: The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 10, 2012
    Inventors: Nobuyuki Takahashi, Shinichi Koizumi
  • Publication number: 20120093759
    Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.
    Type: Application
    Filed: November 17, 2011
    Publication date: April 19, 2012
    Inventor: David J. Vachon
  • Publication number: 20120088671
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Application
    Filed: October 6, 2011
    Publication date: April 12, 2012
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Publication number: 20120082659
    Abstract: Disclosed are compositions and methods related to new targets for cancer treatment.
    Type: Application
    Filed: October 12, 2011
    Publication date: April 5, 2012
    Inventors: Hartmut Land, Helene R. McMurray, Erik R. Sampson
  • Publication number: 20120071430
    Abstract: Bacterial quorum-sensing molecule analogs having the following structures: and methods of reducing bacterial pathogenicity, comprising providing a biological system comprising pathogenic bacteria which produce natural quorum-sensing molecule; providing a synthetic bacterial quorum-sensing molecule having the above structures and introducing the synthetic quorum-sensing molecule into the biological system comprising pathogenic bacteria. Further is provided a method of targeted delivery of an antibiotic, comprising providing a synthetic quorum-sensing molecule; chemically linking the synthetic quorum-sensing molecule to an antibiotic to produce a quorum-sensing molecule-antibiotic conjugate; and introducing the conjugate into a biological system comprising pathogenic bacteria susceptible to the antibiotic.
    Type: Application
    Filed: November 1, 2011
    Publication date: March 22, 2012
    Applicant: Los Alamos National Laboratory
    Inventors: Rashi Iyer, Kumkum Ganguly, Louis A. Silks
  • Publication number: 20120065182
    Abstract: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
    Type: Application
    Filed: November 18, 2011
    Publication date: March 15, 2012
    Applicant: Taro Pharmaceuticals North America, Inc.
    Inventors: Shen GAO, Daniel A. Moros, Satish Asotra
  • Publication number: 20120064145
    Abstract: The present invention discloses a wound dressing which may be a double-layer wound dressing, comprising a polymer material layer in combination with anti-infective antibiotics or anti-infective Chinese herb medicine at the upper layer of the wound dressing, and a porous carbon material layer capable of loading with skin-associated epithelial cells at the lower layer of the wound dressing. The wound dressing with the antibiotics can block effectively the invasion of bacteria in the external environment, thereby preventing the wound from secondary infection. While covering the wound site, the porous carbon material layer with the epithelial cells can thus provide the healthy epithelial cells and attract the surrounding healthy cells to aggregate for secreting collagen so as to promote the wound healing process. According to the present invention, there is an obviously enhancing effect on wound tissue regeneration, restoration and healing, and there is a grant development potential in clinical applications.
    Type: Application
    Filed: January 27, 2011
    Publication date: March 15, 2012
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: YU-SHIN LIN, CHIA-LIN YEH
  • Publication number: 20120058087
    Abstract: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.
    Type: Application
    Filed: December 18, 2009
    Publication date: March 8, 2012
    Applicant: Kobenhavns Universitet
    Inventors: Morten Rønn Petersen, Anders Miki Bojesen
  • Publication number: 20110318416
    Abstract: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition.
    Type: Application
    Filed: September 8, 2011
    Publication date: December 29, 2011
    Applicant: ROYER BIOMEDICAL, INC.
    Inventor: Garfield P. ROYER
  • Publication number: 20110301078
    Abstract: A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria. The compounds include naturally-occurring compounds such as linoleyl ethanolamide, noladin ether, and anandamide, and man-made compounds such as CP55,640 [(?)-cis-3-[2-Hydroxy-4-(l,l-dimethylheptyl)phenyl]-tran s-4-(3-hydroxypropyl)cyclohexanol] and O-2050 [(6aR,10aR)-3-(l-Methanesulfonylamino-4-hexyn-6-yl)-6a, 7,10,1 Oa-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran]. Because these antibacterial compounds have unique modes of action and/or unique chemical scaffolds compared to traditional antibiotics, they are extremely useful against bacteria having resistances to antibiotics.
    Type: Application
    Filed: June 25, 2009
    Publication date: December 8, 2011
    Inventors: John A. Schetz, Sally A. Hoger